What is Pfizer's private equity securities at cost?

Pfizer (PFE) reported private equity securities at cost of $688M in Q1 2026.

How has Pfizer's private equity securities at cost changed year-over-year?

Pfizer's private equity securities at cost decreased by 3.4% year-over-year, from $712M to $688M.

What is the long-term trend for Pfizer's private equity securities at cost?

Over 5 years (2020 to 2025), Pfizer's private equity securities at cost has grown at a 10.0% compound annual growth rate (CAGR), from $432M to $696M.

Pfizer PFE Private equity securities at cost

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+5.0%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$143.68B+11.1%

Enterprise value$206.35B+9.2%

P/E11.9×—

P/S2.3×+0.2×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept pfe:PrivateEquityInvestments.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's private equity securities at cost.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's private equity securities at cost?: Pfizer (PFE) reported private equity securities at cost of $688M in Q1 2026.
How has Pfizer's private equity securities at cost changed year-over-year?: Pfizer's private equity securities at cost decreased by 3.4% year-over-year, from $712M to $688M.
What is the long-term trend for Pfizer's private equity securities at cost?: Over 5 years (2020 to 2025), Pfizer's private equity securities at cost has grown at a 10.0% compound annual growth rate (CAGR), from $432M to $696M.